Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.

Clover Health Investments is trading lower Tuesday afternoon after the Trump administration proposed flat MA payment rates for 2027.

On January 21, 2026, Fiserv announced a partnership with Sumitomo Mitsui Card Company to bring its Clover payments and ...

The New York Mets have spent the last two years chasing a ghost. Specifically, the ghost of a six-man rotation […] ...

Fiserv, Inc.’s FISV growth is fueled by the rising adoption of Software-as-a-Service (SaaS) and payment solutions by business houses. Its new acquisitions and AI innovations aid it in gaining access ...

The Farmers Bank announces five separate internal promotions: two at its Noblesville Financial Center, two at the Fishers Financial Center, and one new assistant vice president. N ...

Regenerative viticulture goes beyond sustainability, improving vineyard ecosystems, soil health, and biodiversity for ...

Phosphate mining is rarely mentioned outside agricultural circles, yet this essential nutrient underpins a critical system on ...

Over the last six months, Clover Health’s shares have sunk to $2.60, producing a disappointing 13.5% loss - a stark contrast ...

UnitedHealth (UNH) stock and its peers drop as the company posts Q4 revenue missing the consensus, and its 2026 revenue ...

The fund has secured commitments from Eli Lilly and Co., Corteva Inc., Elanco Animal Health, Indiana University, Parkview ...

CPP Investments is allocating an initial US$143 million of equity capital to the joint venture, which will have an expected ...